Dialogues in Clinical Neuroscience最新文献

Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-03-06 DOI: 10.1080/19585969.2025.2470426

Paweł Holas, Justyna Kamińska, Marcin Zajenkowski

{"title":"Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).","authors":"Paweł Holas, Justyna Kamińska, Marcin Zajenkowski","doi":"10.1080/19585969.2025.2470426","DOIUrl":"10.1080/19585969.2025.2470426","url":null,"abstract":"Introduction: Psychedelics are gaining recognition for their therapeutic potential in mental health treatment, yet societal attitudes remain divided, influenced by both skepticism and curiosity. This study aimed to develop and validate a scale assessing attitudes toward psychedelics.Methods: Study 1 (n = 1000, convenience sample) explored the factor structure, identifying two dimensions: Openness toward Psychedelics and Concerns toward Psychedelics. Study 2 (n = 843, representative Polish sample) confirmed the scale's validity.Results: The Concerns factor negatively correlated with meaning in life, while the Openness factor was positively associated with openness to experience, agreeableness, conscientiousness, mindfulness, meaning in life, and nature-relatedness. These associations suggest that individuals with greater openness and psychological flexibility may hold more favorable views on psychedelics.Discussion: The Concerns and Openness towards Psychedelics Scale (COPS) is a psychometrically sound tool for assessing attitudes toward psychedelics. Its meaningful correlations with established psychological constructs underscore its utility in research and public health. By providing insight into societal perceptions, COPS may help inform discussions on psychedelic therapy, policy, and education, ultimately fostering a more nuanced understanding of their potential benefits and risks.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"11-21"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The flow cytometric analysis of depression focusing on modern-type depression and hikikomori: Exploring the link between subtypes of depression and immunological imbalances. 抑郁症的流式细胞分析聚焦于现代型抑郁症和隐蔽青年：探索抑郁症亚型与免疫失衡之间的联系。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-01-20 DOI: 10.1080/19585969.2025.2452842

Keitaro Matsuo, Mitsuru Watanabe, Shogo Inamine, Toshio Matsushima, Sota Kyuragi, Yasuhiro Maeda, Ryoko Katsuki, Masahiro Ohgidani, Ryo Yamasaki, Noriko Isobe, Tomohiro Nakao, Takahiro A Kato

{"title":"The flow cytometric analysis of depression focusing on modern-type depression and hikikomori: Exploring the link between subtypes of depression and immunological imbalances.","authors":"Keitaro Matsuo, Mitsuru Watanabe, Shogo Inamine, Toshio Matsushima, Sota Kyuragi, Yasuhiro Maeda, Ryoko Katsuki, Masahiro Ohgidani, Ryo Yamasaki, Noriko Isobe, Tomohiro Nakao, Takahiro A Kato","doi":"10.1080/19585969.2025.2452842","DOIUrl":"10.1080/19585969.2025.2452842","url":null,"abstract":"Introduction: Depression includes different phenotypes. Modern-type depression (MTD) is a gateway disorder to pathological social withdrawal, known as hikikomori. Adverse childhood experiences (ACEs) are also important aetiologies of depression. Recently, immune imbalance has been proposed as a biological basis of depression. We hypothesised that peripheral immunological characteristics may be involved in subtyping of depression.Methods: 21 patients with major depressive disorder (MDD) and 24 healthy controls (HC) were recruited. Peripheral blood mononuclear cells (PBMCs) were examined for surface antigens by flow cytometry. Participants were administered psychological scales such as Patient Health Questionnaire (PHQ)-9, Modern-Type Depression Trait Scale (TACS-22), Hikikomori Questionnaire (HQ-25), Child Abuse and Trauma Scale (CATS).Results: MDD group showed significantly higher percentage of B cells than HC group (p = 0.032). MDD group presented a negative correlation between: PHQ-9 and CD8 T effector memory cells (r= -0.639, p = 0.002), TACS-22 and monocytes (r= -0.459, p = 0.036), HQ-25 and NK T cells (r= -0.638, p = 0.004), CATS and Intermediate monocytes (r= -0.594, p = 0.009).Conclusions: MTD traits, hikikomori tendencies, and ACEs were correlated with specific characteristics of peripheral immune cells. Our results suggest that immune imbalance influences the diverse presentations of depression. Further validation is warranted by large-scale prospective studies.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"13-25"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of perceived side-effects of psychotropic treatments on quality of life in patients with severe mental illness.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/19585969.2025.2463443

Théo Korchia, Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Christelle Andrieu-Haller, Guillaume Fond, Christophe Lançon

{"title":"Impact of perceived side-effects of psychotropic treatments on quality of life in patients with severe mental illness.","authors":"Théo Korchia, Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Christelle Andrieu-Haller, Guillaume Fond, Christophe Lançon","doi":"10.1080/19585969.2025.2463443","DOIUrl":"10.1080/19585969.2025.2463443","url":null,"abstract":"Background: Psychotropic medications are critical in managing severe mental illnesses (SMI) such as schizophrenia, major depressive disorder (MDD) and bipolar disorder. However, these treatments often lead to adverse side effects that can impair patients' quality of life (QoL) and affect treatment adherence.Objective: This study aims to investigate the specific side effects of psychotropic treatments that contribute to a decline in QoL among patients with SMI, independently of treatment adherence.Methods: We conducted a cross-sectional study with 1248 patients diagnosed with SMI, recruited from a university psychiatric unit in Marseille, France. QoL was assessed using the Schizophrenia Quality of Life Scale (SQoL-18), and side effects were measured using the UKU Side Effect Rating Scale. Treatment adherence was evaluated using the Medication Adherence Rating Scale (MARS). Statistical analyses included Pearson correlations and multiple linear regression models to identify predictors of QoL.Results: The study found that side effects, as identified by the UKU scores, could significantly predict a reduction in QoL across multiple domains, including multiple dimensions of QoL and the overall QoL index, independent of treatment adherence. Patients on antipsychotics and benzodiazepines reported higher levels of adverse side effects, which correlated with lower QoL scores. An increase in the number of psychotropic treatment classes was also associated with a significant decline in QoL (p < 0.001).Conclusion: Managing psychic side effects and minimising polypharmacy are critical to improving QoL in patients with SMI. Clinicians should consider these factors when developing personalised treatment strategies to enhance patient outcomes.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"10-19"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of emotional factors in patients with somatic symptom disorder and panic disorder.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-03-25 DOI: 10.1080/19585969.2025.2482123

Hye Youn Park, Yuna Jang, Arum Hong, EKyong Yoon, In-Young Yoon

{"title":"Comparative analysis of emotional factors in patients with somatic symptom disorder and panic disorder.","authors":"Hye Youn Park, Yuna Jang, Arum Hong, EKyong Yoon, In-Young Yoon","doi":"10.1080/19585969.2025.2482123","DOIUrl":"10.1080/19585969.2025.2482123","url":null,"abstract":"Objective: This study investigated the emotional symptom profiles and treatment responses in patients exhibiting overlapping physical symptoms to compare differences between Somatic Symptom Disorder (SSD) and Panic Disorder (PD).Methods: Pharmacotherapy outcomes were analysed in 208 outpatients with SSD (n = 94) and PD (n = 114). Stepwise multivariable logistic regression identified predictors of treatment response, considering variables such as the Clinical Global Impression-Severity (CGI-S), Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory, and State-Trait Anger Expression Inventory. Network analysis explored emotional patterns by estimating network structures for each group.Results: The overall response rate to pharmacotherapy was 23.6% (49/208), with no significant difference between groups. Baseline CGI-S and BDI-II scores were significant predictors of treatment response in both groups, while social phobia score was a significant predictor in PD. Depression and anxiety were related to physical symptoms in both groups, but anger was significantly associated only in SSD. Network analysis revealed that depression was central to other symptoms in SSD, while anxiety was the core symptom in PD, indicating different emotional drivers between the disorders.Conclusions: This study suggests the differences in emotional symptom profiles between SSD and PD. Findings suggest different mechanisms, considering the role of anger in SSD, highlighting the need for more personalised treatments for each disorder.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"56-67"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complex interaction between oestrogen receptor genes, oestradiol, and perinatal mood.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-03-21 DOI: 10.1080/19585969.2025.2482126

Gianna Zorzini, Alexandra Johann, Jelena Dukic, Ulrike Ehlert

{"title":"The complex interaction between oestrogen receptor genes, oestradiol, and perinatal mood.","authors":"Gianna Zorzini, Alexandra Johann, Jelena Dukic, Ulrike Ehlert","doi":"10.1080/19585969.2025.2482126","DOIUrl":"10.1080/19585969.2025.2482126","url":null,"abstract":"Introduction: Genetic variations in oestrogen receptor (ER) genes are associated with inter-individual differences in the sensitivity of ER-α, ER-β and G protein-coupled oestrogen receptor (GPER). These sensitivity differences may modulate susceptibility to mood changes during phases of endogenous oestrogen fluctuations, thereby explaining individual vulnerability. This study examined the association between ER gene variations, oestradiol and perinatal mood disturbances.Methods: A total of 159 women were observed during the perinatal period, providing saliva samples for oestradiol assessment and completing self-report measures of depressive and anxiety symptoms at five time points. Polymorphisms in ER genes were determined from dried blood spots. The associations were analysed using linear mixed models.Results: The ER-α gene haplotypes were associated with perinatal mood disturbances. The CG haplotype was associated with perinatal depressive (p = 0.0162, F-test) and anxiety symptoms (p = 2.396e-05, F-test), whereas the TA haplotype was associated with perinatal anxiety symptoms (p = 0.004, F-test). The interaction between ER gene variations, oestradiol and perinatal mood disturbances was not significant.Conclusions: ER-α gene variations are associated with an increased susceptibility to perinatal mood disturbances. Sensitivity differences in ER-α appear to play a more important role for emotional processes than those in ER-β and GPER, independently of oestradiol levels. This might be explained by ER-α's more dominant expression in the hypothalamus and amygdala.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"24-33"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-03-19 DOI: 10.1080/19585969.2025.2480566

Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz, Ilinca Untu, Romeo-Petru Dobrin, Bogdan-Ionel Tamba

{"title":"Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?","authors":"Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz, Ilinca Untu, Romeo-Petru Dobrin, Bogdan-Ionel Tamba","doi":"10.1080/19585969.2025.2480566","DOIUrl":"10.1080/19585969.2025.2480566","url":null,"abstract":"The increasing prevalence of dementia within an ageing global population, combined with prolonged life expectancy, accentuates Alzheimer's disease (AD) as a multifaceted healthcare challenge. This challenge is further compounded by the limited therapeutic options currently available. Addressing the intricacies of AD management, the mitigation of comorbidities has emerged as a pivotal facet of treatment. Comorbid conditions, such as neurobehavioral symptoms, play a role in shaping the clinical course, management, and outcomes of this pathology; highlighting the importance of comprehensive care approaches for affected individuals. Exploration of psychedelic compounds in psychiatric and palliative care settings has recently uncovered promising therapeutic potential, enhancing neuroplasticity, emotional processing and connection. These effects are particularly relevant in the context of AD, where psychedelic therapy offers hope not only for mitigating core symptoms but also for addressing the array of comorbidities associated with this condition. The integration of this comprehensive method offers a chance to significantly enhance the care provided to those navigating the intricate landscape of AD. Therefore, the current paper reviews the intricate link between more frequent additional health conditions that may coexist with dementia, particularly in the context of AD, and explores the therapeutic potential of psychedelic compounds in addressing these concurrent conditions.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"1-12"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of attention deficit hyperactivity disorder in homeless children and adolescents: A systematic review and meta-analysis.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-04-02 DOI: 10.1080/19585969.2025.2486355

Charles Denis, Denis Boucaud-Maitre, Jérôme Brunelin, Lucie Jurek, William Vallet, Caroline Demily

{"title":"Prevalence of attention deficit hyperactivity disorder in homeless children and adolescents: A systematic review and meta-analysis.","authors":"Charles Denis, Denis Boucaud-Maitre, Jérôme Brunelin, Lucie Jurek, William Vallet, Caroline Demily","doi":"10.1080/19585969.2025.2486355","DOIUrl":"10.1080/19585969.2025.2486355","url":null,"abstract":"Introduction: This systematic review and meta-analysis aimed to examine the prevalence of Attention deficit hyperactivity disorder (ADHD) in homeless children and adolescents, and the factors that may influence its prevalence.Methods: Relevant publications in Medline, Web of Science, Scopus and PsycINFO were systematically searched to identify studies on the prevalence of ADHD in homeless children and adolescents (≤19 years). The extracted data were pooled using a random-effects model.Results: Thirteen studies involving 2878 homeless children and adolescents were included (mean age: 12.0 years, sex F/M: 0.43). The prevalence rates of ADHD vary considerably across studies, ranging from 1.6% to 64.5%. The pooled prevalence of ADHD was 22.8% (95% CI 12.9-34.4%, I2 =98%). Meta-regression analyses indicated that age (slope = 0.046; p = .042) significantly increased ADHD prevalence. The prevalence of ADHD in studies with a mean age ≥ 12 years (43.1%, 95% CI 26.5-60.4%) was higher than those with a mean age < 12 years (13.1%, 95%CI 4.3-25.6).Conclusion: Despite the high heterogeneity of the studies, we observed that ADHD could affect almost a quarter of homeless children and adolescents. Reintegrating them into care systems and ensuring access to public health interventions tailored for homeless families and youth is imperative for breaking the cycle of homelessness and improving long-term trajectories.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"86-97"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antipsychotic off-label use in the 21st century: An enduring public health concern. 21世纪抗精神病药物的标签外使用：一个持久的公共卫生问题。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-01-10 DOI: 10.1080/19585969.2025.2449833

Hélène Verdoux

{"title":"Antipsychotic off-label use in the 21st century: An enduring public health concern.","authors":"Hélène Verdoux","doi":"10.1080/19585969.2025.2449833","DOIUrl":"10.1080/19585969.2025.2449833","url":null,"abstract":"Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms. Observational studies confirm the persisting high rate of antipsychotic OLU prescription in two out of three youths and 30-60% of adults using antipsychotics. Increasing rates of low-dose quetiapine prescriptions for anxiety or sleep symptoms are paradigmatic of the current public health concern regarding antipsychotic OLU. Such prescriptions receive impetus from industry-funded marketing strategies and prescribers' feeling of innocuousness, with a resulting underestimation of the risk of adverse drug reactions (ADR). However, antipsychotic OLU should be neither trivialised nor demonised since it may be the only therapeutic option in persons with resistant psychiatric disorders or serious ADR with labelled drugs. To reduce the populational impact of antipsychotic OLU, it is necessary to better control the influence of the pharmaceutical industry regarding newly marketed drugs and to better inform prescribers and users about the risks associated with OLU prescribing.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"1-12"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of causal relationships between genetic liability to inflammatory bowel disease and autism spectrum disorder by Mendelian randomization analysis.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/19585969.2025.2460798

Ruijie Zeng, Rui Jiang, Wentao Huang, Huihuan Wu, Zewei Zhuo, Qi Yang, Jingwei Li, Felix W Leung, Weihong Sha, Hao Chen

{"title":"Evaluation of causal relationships between genetic liability to inflammatory bowel disease and autism spectrum disorder by Mendelian randomization analysis.","authors":"Ruijie Zeng, Rui Jiang, Wentao Huang, Huihuan Wu, Zewei Zhuo, Qi Yang, Jingwei Li, Felix W Leung, Weihong Sha, Hao Chen","doi":"10.1080/19585969.2025.2460798","DOIUrl":"10.1080/19585969.2025.2460798","url":null,"abstract":"Background: Emerging observational studies have indicated the association between autism spectrum disorder (ASD) and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), whereas the causality remains unknown.Methods: Summary-level data from large-scale genome-wide association (GWAS) studies of IBD and ASD were retrieved. Mendelian randomisation analyses were performed with a series of sensitivity tests.Results: Genetic predisposition to ASD was not associated with the risk of IBD (odds ratio [OR] = 0.99, 95% confidence interval [CI = 0.91-1.06, p = 0.70; OR [95% CI]: 1.03 [0.93-1.13], p = 0.58 for CD; OR [95% CI]: 0.96 [0.87-1.05], p = 0.37 for UC) in the IIBDGC dataset. In the FinnGen dataset, their causal effects were unfounded (OR [95% CI]: 1.04 [0.94-1.15], p = 0.49 for IBD; OR [95% CI]: 1.08 [0.89-1.31], p = 0.42 for CD; OR [95% CI]: 1.00 [0.88-1.13], p = 0.95 for UC). In the meta-analysis of two datasets, the OR was 1.01 (95% CI 0.96-1.07, p = 0.45). For the risk of ASD under genetic liability to IBD, the OR from meta-analysis was 1.03 (95% CI 1.01-1.05, p = 0.01).Conclusion: Our findings indicate genetic predisposition to ASD might not increase the risk of IBD, whereas genetic liability to IBD is associated with an increased risk of ASD. Further investigations using more powerful datasets are warranted.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"26-34"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gambling disorder comorbidity a narrative review.

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2025-12-01 Epub Date: 2025-04-03 DOI: 10.1080/19585969.2025.2484288

Rishi Sharma, Aviv Weinstein

{"title":"Gambling disorder comorbidity a narrative review.","authors":"Rishi Sharma, Aviv Weinstein","doi":"10.1080/19585969.2025.2484288","DOIUrl":"10.1080/19585969.2025.2484288","url":null,"abstract":"Introduction: Problematic and pathological gambling (PG) lead to major adverse consequences for individuals, their families, and society and is highly comorbid with numerous other mental health disorders.Methods: This narrative review summarized population-based, cross-sectional, treatment and prospective studies on gambling disorder and comorbidity over the past 14 years.Results: These studies show a high rate of comorbidity of PG and substance and alcohol use disorders, mood and anxiety disorders. Prospective studies indicate that, in some cases, gambling precedes the onset of the comorbid disorder, while in other instances, the temporal relationship is reversed. Women face greater psychiatric comorbidity and are more likely to have mood disorders, suicidality, mania, anxiety and alcohol dependence. Treatment of PG can be effective by improving the gambling and depressive symptoms of PG.Conclusions: Over the past 15 years, significant progress has been made in understanding and treating GD and its psychiatric comorbidities, with evidence highlighting the reciprocal relationships between GD and conditions like substance use, mood and anxiety disorders.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"27 1","pages":"1-18"},"PeriodicalIF":8.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0